IgGenix

Executive Summary

IgGenix is a US-based biotechnology company pioneering monoclonal antibody therapies for severe allergic and autoimmune diseases. Founded in 2018 and headquartered in South San Francisco, the company has raised $40 million to advance its platform, which isolates rare, high-affinity antibodies from B cells of naturally protected individuals. This approach aims to produce transformative treatments for life-threatening conditions such as food allergies and autoimmune disorders. Currently in Phase 2 clinical development, IgGenix's lead program targets peanut allergy, with potential to address other allergens and autoimmune indications. The company's differentiated platform and focus on high-unmet-need diseases position it as a notable player in the immunology space, though it faces typical biotech risks including clinical trial outcomes and funding needs. With a growing pipeline and strategic partnerships, IgGenix is poised for near-term value inflection points.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead peanut allergy candidate60% success
• Q4 2026Initiation of Phase 3 clinical trial for lead candidate50% success
• Q2 2027Strategic partnership or licensing deal for broader pipeline40% success